Results 171 to 180 of about 3,628 (221)
Some of the next articles are maybe not open access.
Cangrelor for treatment of arterial thrombosis
Expert Opinion on Pharmacotherapy, 2014Percutaneous coronary intervention (PCI) is a highly effective treatment for obstructive coronary artery disease. Oral platelet P2Y12 receptor antagonists reduce ischemic events in patients treated with PCI. However, there are several limitations to their use, including variable pharmacodynamics, a slow onset and offset, and in those patients who are ...
Joseph A, Walsh, Matthew J, Price
openaire +2 more sources
Update on the clinical development of cangrelor
Expert Review of Cardiovascular Therapy, 2010Antiplatelet drugs represent the cornerstone of treatment for cardiovascular atherothrombotic disease. Dual oral antiplatelet therapy with aspirin and oral ADP-receptor antagonists, such as clopidogrel, has been the standard choice for prevention of ischemic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary ...
Masafumi, Ueno +2 more
openaire +2 more sources
Cangrelor for Treatment of Coronary Thrombosis
Annals of Pharmacotherapy, 2006Objective: To review and assess available literature on the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical studies, adverse events, drug interactions, special populations, and dosing and administration for cangrelor, a product in late stage Phase II clinical trials.
Susan E, Fugate, Laura A, Cudd
openaire +2 more sources
Current status of data on cangrelor
Pharmacology & Therapeutics, 2016P2Y12 receptor inhibition in addition to aspirin is the cornerstone of treatment in patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). Despite advances in contemporary antithrombotic therapy, periprocedural thrombotic complications such as myocardial infarction and stent thrombosis remain a major
Arman, Qamar, Deepak L, Bhatt
openaire +2 more sources
Cangrelor in percutaneous coronary intervention
Expert Review of Clinical Pharmacology, 2009Cangrelor is a novel, intravenous P2Y12 receptor antagonist in development for use in percutaneous coronary intervention. Currently in Phase III testing, the reversible platelet inhibitor provides several inherent advantages over other P2Y12 receptor antagonists in this setting for the prevention of adverse cardiac events.
Julie H, Oestreich, Steven R, Steinhubl
openaire +2 more sources
The Fall and Rise of Cangrelor
Drug Development Research, 2013Abstract Clinical Development Phases I‐III Regulatory, Quality, Manufacturing The antagonism of the platelet P2Y12 receptor is essential for the treatment of patients undergoing percutaneous coronary intervention (PCI). Cangrelor is an intravenous P2Y12 receptor antagonist that being both reversible and very short acting has the potential to ...
Sergio Leonardi +3 more
openaire +1 more source
Cangrelor for the treatment of patients with Arterial Thrombosis
Expert Opinion on Pharmacotherapy, 2018All oral P2Y12 receptor blockers are associated with some degree of delayed onset and offset of pharmacodynamic (PD) effects in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Although intravenous glycoprotein IIb/IIIa inhibitors are associated with rapid onset of action, they are also associated with ...
Udaya, Tantry +4 more
openaire +2 more sources